Cargando…

Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation

BACKGROUND: Intrauterine growth factor (IUGR) is one of the most important causes of neonatal mortality. The aim of this study was to evaluate the therapeutic effect of utrogestan on the treatment of IUGR and its complications. MATERIALS AND METHODS: In this clinical trial, 66 pregnant women with id...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Belgheis, Matinfar, Marzieh, Drees, Fatemeh, Shabanian, Sheida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792872/
https://www.ncbi.nlm.nih.gov/pubmed/33457328
http://dx.doi.org/10.4103/abr.abr_27_20
_version_ 1783633878541402112
author Mohammadi, Belgheis
Matinfar, Marzieh
Drees, Fatemeh
Shabanian, Sheida
author_facet Mohammadi, Belgheis
Matinfar, Marzieh
Drees, Fatemeh
Shabanian, Sheida
author_sort Mohammadi, Belgheis
collection PubMed
description BACKGROUND: Intrauterine growth factor (IUGR) is one of the most important causes of neonatal mortality. The aim of this study was to evaluate the therapeutic effect of utrogestan on the treatment of IUGR and its complications. MATERIALS AND METHODS: In this clinical trial, 66 pregnant women with idiopathic IUGR embryos were enrolled. Patients in the intervention group, in addition to receiving routine treatment of control group (high-protein diet, resting), took utrogestan capsules (100 mg) twice daily. The primary and secondary outcomes of the disease were recorded in a checklist. Data were analyzed using SPSS 18 using an independent t-test, Chi-square test, and Fisher's exact test. RESULTS: In the intervention group, mean neonatal weight (P = 0.003), mean neonatal Apgar score (P = 0.001), and mean gestational age at birth (P = 0.001) were significantly higher than those in the control group. There was no neonatal death in the intervention group, whereas in the control group, four cases of neonatal death were observed (P = 0.03). In the majority of subjects in the intervention group, resistance index, and pulsatility index of the umbilical artery decreased (P = 0.002). The difference in abdominal circumference and gestational age in the intervention group decreased (P = 0.01). In the intervention group, the diastolic flow of the umbilical artery increased (P = 0.002). CONCLUSION: Utrogestan was effective as an inexpensive and effective way to treat IUGR and improve pregnancy outcomes.
format Online
Article
Text
id pubmed-7792872
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-77928722021-01-15 Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation Mohammadi, Belgheis Matinfar, Marzieh Drees, Fatemeh Shabanian, Sheida Adv Biomed Res Original Article BACKGROUND: Intrauterine growth factor (IUGR) is one of the most important causes of neonatal mortality. The aim of this study was to evaluate the therapeutic effect of utrogestan on the treatment of IUGR and its complications. MATERIALS AND METHODS: In this clinical trial, 66 pregnant women with idiopathic IUGR embryos were enrolled. Patients in the intervention group, in addition to receiving routine treatment of control group (high-protein diet, resting), took utrogestan capsules (100 mg) twice daily. The primary and secondary outcomes of the disease were recorded in a checklist. Data were analyzed using SPSS 18 using an independent t-test, Chi-square test, and Fisher's exact test. RESULTS: In the intervention group, mean neonatal weight (P = 0.003), mean neonatal Apgar score (P = 0.001), and mean gestational age at birth (P = 0.001) were significantly higher than those in the control group. There was no neonatal death in the intervention group, whereas in the control group, four cases of neonatal death were observed (P = 0.03). In the majority of subjects in the intervention group, resistance index, and pulsatility index of the umbilical artery decreased (P = 0.002). The difference in abdominal circumference and gestational age in the intervention group decreased (P = 0.01). In the intervention group, the diastolic flow of the umbilical artery increased (P = 0.002). CONCLUSION: Utrogestan was effective as an inexpensive and effective way to treat IUGR and improve pregnancy outcomes. Wolters Kluwer - Medknow 2020-09-30 /pmc/articles/PMC7792872/ /pubmed/33457328 http://dx.doi.org/10.4103/abr.abr_27_20 Text en Copyright: © 2020 Advanced Biomedical Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Mohammadi, Belgheis
Matinfar, Marzieh
Drees, Fatemeh
Shabanian, Sheida
Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title_full Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title_fullStr Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title_full_unstemmed Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title_short Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title_sort evaluating the effect of utrogestan on idiopathic intrauterine growth retardation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792872/
https://www.ncbi.nlm.nih.gov/pubmed/33457328
http://dx.doi.org/10.4103/abr.abr_27_20
work_keys_str_mv AT mohammadibelgheis evaluatingtheeffectofutrogestanonidiopathicintrauterinegrowthretardation
AT matinfarmarzieh evaluatingtheeffectofutrogestanonidiopathicintrauterinegrowthretardation
AT dreesfatemeh evaluatingtheeffectofutrogestanonidiopathicintrauterinegrowthretardation
AT shabaniansheida evaluatingtheeffectofutrogestanonidiopathicintrauterinegrowthretardation